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OBJECTIVES To investigate whether myocardial beta-adrenoceptor (beta-AR) downregulation precedes
and predicts left ventricular (LV) dilation after acute myocardial infarction (AMI), we
measured beta-AR density within four weeks of AMI and correlated it with serial
measurements of LV volumes.
BACKGROUND Patients who develop heart failure following AMI have an increased sympathetic drive to the
heart within the first four weeks after infarction.
METHODS We prospectively studied 61 patients in whom AMI was the first presentation of coronary
artery disease (CAD) and with no signs of heart failure. The LV volumes were measured one,
three, and six months after AMI by echocardiography. Beta-AR density was measured using
positron emission tomography with S-[11C]CGP 12177. Seventeen matched healthy
volunteers served as controls.
RESULTS Whole heart beta-AR density was lower in patients than in controls (6.25  0.98 pmol/g vs.
8.32  2.14 pmol/g, p  0.0001). In patients, beta-AR density was inversely correlated with
end-systolic and end-diastolic volumes six months after AMI. Patients whose LV was dilated
at six months had a lower beta-AR density in noninfarcted myocardium than patients without
dilation (6.15 pmol/g vs. 6.98 pmol/g, p  0.008). In addition, beta-AR density in
noninfarcted myocardium was higher when the infarct-related artery was patent (6.87  1.14
pmol/g vs. 5.76  0.86 pmol/g occluded, p  0.01).
CONCLUSIONS Myocardial beta-AR density is reduced after AMI in the absence of heart failure, and the
reduction predicts later LV dilation. These data are suggestive of an enhanced sympathetic
drive to the heart, having an important etiologic role in LV remodeling after AMI. (J Am
Coll Cardiol 2002;40:1216–24) © 2002 by the American College of Cardiology Foundation
Congestive heart failure (CHF) is common and, as an
absolute cause of death, mortality is increasing (1). In about
70% of cases, it is secondary to coronary artery disease
(CAD) (2). In most of these patients there is evidence of a
previous acute myocardial infarction (AMI), especially
when the latter is extensive, transmural, and involves the
anterior wall of the left ventricle (LV) (3). Development of
overt CHF after AMI is often slow and is preceded by an
asymptomatic phase in which changes in the shape, size,
and properties of the LV occur (remodeling) (4).
A number of mechanisms contribute to LV remodeling
(5), among which enhanced activation of the sympathetic
nervous system (SNS) plays a major role. Myocardial
beta-adrenoceptors (beta-AR), measured from endomyo-
cardial biopsies, are downregulated in patients with overt
CHF and the degree of receptor downregulation is related
to the severity of CHF (6). Furthermore, these patients have
higher levels of circulating catecholamines, which are in-
versely related to prognosis (7).
Positron emission tomography (PET) with the nonselec-
tive beta-AR antagonist S-[11C]CGP 12177 (CGP) allows
the noninvasive measurement of regional myocardial
beta-AR density (Bmax) in humans in vivo. Merlet et al. (8)
demonstrated downregulation of beta-AR in patients with
CHF due to idiopathic dilated cardiomyopathy. Using the
same technique, we demonstrated progressive beta-AR
downregulation in those patients with hypertrophic cardio-
myopathy (HCM) who proceed to LV dilation and CHF
(9).
We hypothesized that the degree of myocardial beta-AR
downregulation measured in the subacute phase after AMI
might be predictive of subsequent LV remodeling. There-
fore, we set up a prospective study of patients with AMI as
their first presentation of CAD. Serial measurements of LV
volumes were carried out up to six months after infarction,
and beta-AR density and plasma catecholamines were
measured within four weeks of AMI.
METHODS
Study population. Sixty-one patients (age 52 11 years, 9
women) were recruited from St. Mary’s, Hammersmith,
Ealing, and Charing Cross Hospitals in London. Acute
myocardial infarction was diagnosed on the basis of history,
electrocardiogram, and cardiac enzyme rise (creatine kinase
greater than twice the upper limit of normal). Exclusion
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criteria were previous angina, hypertension, diabetes, renal
failure, and significant CAD in arteries other than the
infarct-related artery. Thus, if a noninfarct-related artery
had a stenosis 50% in two orthogonal projections, or 75%
in a single projection, the patient was excluded. Part of the
study protocol was that patients would undergo diagnostic
coronary angiography within 10 days of their AMI, with
percutaneous coronary intervention to the relevant lesion as
appropriate.
Treatment for AMI was left completely to the admitting
physician and could include acute (i.e., intravenous) beta-
blockade, but patients who required long-term beta-
blockade were excluded (Table 1). (Because, during the
period of recruitment [1995 to 1998], it was not routine
practice in our institutions to use chronic beta-blockade for
post-myocardial infarction patients, whether in heart failure
or not, we do not believe that our protocol selectively
excluded a subset of patients who would have required
chronic beta-blockade.)
Seventeen healthy volunteers (9 men, age 53  12 years,
p  NS vs. patients) were studied as controls for the
measurement of myocardial beta-AR. They had no history
of CAD and had normal resting and negative exercise
electrocardiogram.
Study Protocol
Echocardiography. Patients were studied by echocardiog-
raphy at one to two weeks, one month, and six months after
AMI using a Challenge 7000 echocardiograph (Esaote
Biomedica, Florence, Italy). Both end-systolic volume
(ESV) and end-diastolic volume (EDV) were measured
using a single-plane area-length method (10). The average
of three measurements was used for each parameter. Pa-
tients were deemed to have undergone LV dilation if both
ESV3/ESV1 and EDV3/EDV1 were higher than 1.1, or if
either one of these ratios was 1.2—that is, 10% or 20%
difference from baseline (11).
PET scanning. Patients underwent PET scanning using
an ECAT 931-08/12 scanner (CTI/Siemens, Knoxville,
Tennessee) two to four weeks after AMI. After a 20-min
transmission scan, the blood pool was imaged using inhaled
C15O. After 10 min, myocardial blood flow (MBF) was
measured using H2
15O (12).
Subsequently, myocardial beta-AR density was measured
using CGP (13). Briefly, the first dose of CGP with high
specific activity (159  29 MBq; 5.7  2.3 g) was infused
intravenously over 2 min and followed, 30 min later, by
a second low specific activity injection (300  67 MBq;
28.6  5.8 g) infused over 2 min. A 55-frame dynamic
emission scan (12) was used to measure the temporal and
spatial distribution of the tracer in vivo. Venous blood was
continuously withdrawn and passed through a bismuth
germanium oxide counting system to assess changes in CGP
blood concentration with time. This information was used
to correct the CGP scan for vascular activity. Five calibra-
tion blood samples were taken during this period and
assayed for [11C]-activity in a well counter, cross-calibrated
with the scanner (13).
PET DATA ANALYSIS. All sinograms were normalized, cor-
rected for attenuation, and then reconstructed to provide
transaxial images with a spatial resolution of 8.4 mm full
width at half maximum and a slice thickness of 6.6 mm full
width at half maximum. Images were resliced in short axis,
and 12 slices were obtained from the mitral valve plane to
the apex of the heart. Regions of interest (ROIs) were
defined by dividing the LV myocardium into anterior,
septal, lateral, and inferior regions, further subdivided into
16 segments (13,14). A whole-heart ROI was also created
by averaging all pixels within the area between the outer and
inner trace for all 12 slices. These ROIs were then applied
to all emission images of the different scans. The ROIs of
the myocardial territory subtended by the infarct-related
artery were termed “infarcted myocardium”; the ROIs of the
myocardial territory subtended by an artery reciprocal to the
infarct-related artery were termed “remote myocardium.”
Thus, the anterior and septal ROIs were considered “re-
mote” with respect to an inferior infarct, and the inferior
ROI was considered “remote” with respect to an anterior
infarct.
MBF MEASUREMENT. The MBF (ml/min/g) was calculated
by fitting the arterial input (obtained from a left atrial ROI)
and tissue time-activity curves from the blood flow scan to
a single-tissue compartment tracer kinetic model (12),
which includes corrections for partial volume effect and
spillover of activity from the LV chamber into myocardial
ROIs.
MEASUREMENT OF BETA-AR DENSITY. Myocardial time-
activity curves were corrected for radioactive decay and for
vascular activity (13). The sections of the curve correspond-
ing to the two slow clearance phases, which represent the
dissociation of CGP bound to beta-AR, were exponentially
extrapolated back to the start of the infusions. Beta-
adrenoceptor density was determined as the maximum
number of available specific CGP binding sites per gram of
tissue (Bmax) in the ROIs (13). The Bmax values were
Abbreviations and Acronyms
AMI  acute myocardial infarction
beta-AR  beta-adrenoceptor
Bmax  myocardial beta-adrenoceptor density
CAD  coronary artery disease
CGP  S-[11C]CGP 12177
CHF  congestive heart failure
EDV  end-diastolic volume
ESV  end-systolic volume
HCM  hypertrophic cardiomyopathy
LV  left ventricle/ventricular
MBF  myocardial blood flow
PET  positron emission tomography
ROI  region of interest
SNS  sympathetic nervous system
TIMI  Thrombolysis In Myocardial Infarction
1217JACC Vol. 40, No. 7, 2002 Spyrou et al.
October 2, 2002:1216–24 Myocardial Beta-AR After Acute Infarction
Table 1. Treatment, Left Ventricular Volumes, and TIMI Flow for Each of the 61 Patients
Patient
No. Treatment
EDV1
(ml)
EDV3
(ml)
ESV1
(ml)
ESV3
(ml) ESV EDV
TIMI
Flow A
TIMI
Flow B
1 ASAACEI 73 127 43 67 1.56 1.74 1 1
2 ASAACEICCB 72 110 39 67 1.72 1.53 1 3
3 ASAACEICCB 101 149 58 90 1.55 1.48 1 3
4 ASAACEICCB 86 123 45 61 1.36 1.43 2 3
5 ASAACEI 138 120 72 60 0.83 0.87 3 3
6 ASAACEICCB 60 62 36 35 0.97 1.03 2 3
7 ASAACEI 103 92 55 54 0.98 0.89 1 2
8 ASA 144 112 81 58 0.72 0.78 2 3
9 ASA 93 109 44 42 0.95 1.17 1 3
10 ASA 100 71 62 38 0.61 0.71 3 3
11 ASAACEICCB 92 81 54 34 0.63 0.88 2 3
12 ASAACEICCB 100 109 53 65 1.23 1.09 1 3
13 ASAACEI 82 151 31 91 2.94 1.84 0 2
14 ASACCB 82 75 36 25 0.69 0.91 2 3
15 ASAACEI 59 106 35 61 1.74 1.80 1 3
16 ASA 107 112 52 55 1.06 1.05 1 3
17 ASACCB 93 184 55 125 2.27 1.98 2 2
18 ASACCB 109 106 72 62 0.86 0.97 1 1
19 ASAACEI 132 174 76 115 1.51 1.32 2 2
20 ASA 148 171 90 67 0.74 1.16 2 3
21 ASAACEI 152 194 81 84 1.04 1.28 2 3
22 ASA 124 141 63 78 1.24 1.14 2 3
23 ASA 101 109 46 53 1.15 1.08 2 3
24 ASA 109 129 59 80 1.36 1.18 0 3
25 ASACCB 236 278 142 167 1.18 1.18 2 3
26 ASACCB 79 94 39 32 0.82 1.19 2 3
27 ASAACEICCB 92 84 53 41 0.77 0.91 2 3
28 ASA 116 112 57 50 0.88 0.97 2 3
29 ASAACEICCB 135 158 67 86 1.28 1.17 2 3
30 ASACCB 103 108 58 67 1.16 1.05 1 3
31 ASACCB 114 111 55 62 1.13 0.97 1 3
32 ASACCB 115 108 41 55 1.34 0.94 2 3
33 ASACCB 101 102 49 45 0.92 1.01 3 3
34 ASAACEI 93 107 46 50 1.09 1.15 2 3
35 ASAACEICCB 105 101 61 54 0.89 0.96 2 3
36 ASAACEICCB 123 106 63 49 0.78 0.86 2 3
37 ASACCB 132 132 65 61 0.94 1.00 2 2
38 ASAACEICCB 133 201 79 119 1.51 1.51 1 3
39 ASAACEI 95 56 47 27 0.57 0.59 1 3
40 ASAACEI 138 149 94 96 1.02 1.08 0 3
41 ASAACEICCB 103 99 58 64 1.10 0.96 1 3
42 ASA 130 111 68 47 0.69 0.85 2 3
43 ASA 118 112 69 44 0.64 0.95 2 3
44 ASAACEICCB 111 96 65 55 0.85 0.86 2 3
45 ASAACEI 145 82 76 42 0.55 0.57 2 3
46 ASA 154 124 103 70 0.68 0.81 2 3
47 ASACCB 109 121 53 49 0.92 1.11 2 3
48 ASACCBACEI 198 126 99 69 0.70 0.64 2 3
49 ASACCB 117 112 43 60 1.40 0.96 1 2
50 ASAACEI 153 125 74 67 0.91 0.82 0 3
51 ASA 155 135 74 77 1.04 0.87 2 3
52 ASACCB 163 197 90 135 1.50 1.21 0 2
53 ASACCB 100 107 44 49 1.11 1.07 3 3
54 ASAACEICCB 78 114 42 53 1.26 1.46 2 3
55 ASACCB 172 128 117 66 0.56 0.74 2 3
56 ASACCB 115 107 48 56 1.17 0.93 1 3
57 ASAACEI 110 119 69 91 1.32 1.35 1 2
58 ASAACEI 132 100 68 46 0.68 0.76 1 3
59 ASACCB 129 144 41 79 1.93 1.12 2 3
60 ASAACEI 224 180 115 88 0.77 0.80 2 3
61 ASACCB 114 110 50 62 1.24 0.96 2 3
ASA  aspirin; ACEI  angiotensin-converting enzyme inhibitor; CCB  calcium channel blocker; ESV1  end-systolic volume at one week; ESV3  end-systolic volume
at six months; EDV1  end-diastolic volume at one week; EDV3  end-diastolic volume at six months; ESV  ESV3/ESV1; EDV  EDV3/EDV1; TIMI A 
Thrombolysis In Myocardial Infarction flows at baseline (after thrombolysis, but before percutaneous interventions); TIMI B  Thrombolysis In Myocardial Infarction flows
after percutaneous interventions.
corrected for partial volume effect and movement using the
measured values of tissue fraction (12). In infarcted regions
the presence of significant tissue thinning and fibrosis might
lead to erroneously lower Bmax owing to a dilutional effect of
scar. To minimize the effect of such thinning and fibrosis,
all beta-AR values were corrected for partial volume using
the perfusible tissue index (15). This is derived from the
H2
15O scan and provides an estimate of the fraction of
viable tissue within the volume of interest capable of
exchanging rapidly the freely diffusible tracer H2
15O.
Therefore, beta-AR densities are reported per milliliter of
perfusible and hence viable tissue.
Plasma catecholamine assay. Venous samples were taken
after subjects had been relaxed and recumbent for 30 min.
Adrenaline and noradrenaline were assayed using high-
performance liquid chromatography with electrochemical
detection (13).
Statistical Analysis
Values are expressed as mean  SD. Analysis of variance
was carried out to assess the differences in beta-AR and
myocardial blood flow among the myocardial ROIs within
groups, with the Scheffe´ test to localize the source of any
differences. The two-tailed unpaired Student t test was used
to compare the ages and the values of myocardial beta-AR
between each patient group and its matched control subset.
Regression analysis was performed using standard tech-
niques. The relationship between Thrombolysis In Myocar-
dial Infarction (TIMI) flows and changes in LV volumes at
six months was assessed through ordered classification
analysis (16). A p value of0.05 was considered significant.
RESULTS
Clinical outcomes. The proportion of patients with ante-
rior or anteroseptal infarction was 44%. The number of
patients with ST-elevation infarcts was 44/61 and non–ST-
elevation MI was 17/61. The peak creatine kinase levels of
these groups were, respectively, 1,798  1,557 IU/l and
1,233  993 IU/l, p  NS. Thrombolytics were given to
93% of patients and percutaneous revascularization was
attempted in 89% of patients. The TIMI flows at baseline
(after thrombolysis, but prior to percutaneous interventions)
and after percutaneous interventions are shown in Table 1.
Although no patient had overt CHF at enrollment, two
patients developed CHF by six months (one patient [17]
was in New York Heart Association functional class III and
one [57] in class IV). The former patient died suddenly at
home three years after the AMI.
Hemodynamics and LV volumes. Resting heart rate was
63  9 beats/min at one week and 63  10 beats/min at six
months (p  NS). Systolic blood pressure was 116  17
mm Hg at one week and 119  16 mm Hg at six months
(p  NS). Diastolic blood pressure was 71  8 mm Hg at
one week and 72  8 mm Hg at six months (p  NS). Left
ventricular volumes at one week and six months and their
ratios are reported in Table 1. The ESV2 and EDV2 data
were little different from the values of ESV1 and EDV1 and
have therefore been omitted. The ratios ESV3/ESV1
(ESV) and EDV3/EDV (EDV), as indices of LV dila-
tion, are also reported in Table 1.
MBF, beta-AR, and circulating catecholamines. These
data are reported in Table 2. Resting MBF in remote
myocardium was significantly higher than that in the
infarcted zone, although both were within the normal range
(17). The whole-heart beta-AR was significantly lower in
the patients compared to controls (6.25  0.98 pmol/g vs.
8.32  2.14 pmol/g, p  0.0001). This difference remained
significant for the infarct-related territory (6.22  1.34
pmol/g, p  0.0002 vs. controls) and remote territory
(6.70  1.17 pmol/g, p  0.0003 vs. controls), although no
significant difference existed between beta-AR in the
infarct-related territory and the remote myocardium within
the patient group.
One month after AMI, at the time of PET, patients
had lower circulating noradrenaline than controls (1.61 
0.96 nmol/l vs. 2.84  1.20 nmol/l, p  0.0004), whereas
the adrenaline was not different (0.23 0.16 nmol/l vs. 0.30
 0.21 nmol/l, p  NS).
Interrelations of measured parameters. The changes in
LV end-systolic (ESV) and end-diastolic volume (EDV)
are shown in Table 1. Significant inverse correlations were
observed between the changes in ESV and EDV six months
after AMI and beta-AR densities measured one month after
AMI (Figs. 1 and 2).
Patients in whom LV volumes were unchanged or de-
creased showed no significant difference from those in
whom there had been an increase in LV volumes in terms
of beta-AR in the territory of the infarct-related artery
(6.30 pmol/g vs. 6.05 pmol/g, p  NS). However, for the
remote myocardial territory, beta-AR was significantly
lower in patients with LV dilation (6.15 pmol/g) compared
to those without (6.98 pmol/g, p  0.008) (Fig. 3). In
addition, a higher TIMI flow score after percutaneous
revascularization was associated with improved LV volumes
at follow-up (Table 3).
No correlations were seen between circulating cat-
echolamines and changes in LV volumes; neither were any
correlations seen between circulating catecholamines and
beta-AR.
DISCUSSION
Summary of findings. The present study shows that 1)
myocardial beta-AR is reduced in the subacute phase after
AMI, in the absence of symptoms and signs of CHF; 2) the
changes in myocardial beta-AR occurred in the absence of
an increase in circulating catecholamines; 3) the degree of
downregulation of myocardial beta-AR is predictive of later
increase in LV volumes; and 4) the degree of LV volume
change at six months is inversely related to the TIMI flow
in the subacute phase.
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Table 2. Myocardial Beta-AR Density and Blood Flow for Each of the 61 Patients
Patient No.
Whole-Heart
Beta-AR
Infarct ROI
Beta-AR
Remote ROI
Beta-AR
Infarct
ROI MBF
Remote
ROI MBF
Whole-Heart
MBF
1 6.01 6.97 5.03 0.69 1.30 0.82
2 6.40 6.19 7.93 0.69 1.11 0.91
3 4.93 3.66 4.86 0.91 1.00 0.80
4 3.92 3.49 4.54 1.00 0.83 0.98
5 5.88 5.05 8.44 1.00 1.06 1.00
6 5.53 4.77 6.82 1.15 1.57 1.28
7 7.00 6.59 8.86 0.99 0.50 0.76
8 4.47 4.59 4.56 0.70 0.94 0.86
9 5.56 5.39 7.21 1.05 0.83 0.88
10 5.91 6.74 6.57 0.86 1.61 1.19
11 5.13 5.08 5.04 1.12 0.93 1.06
12 4.73 6.03 4.81 0.92 0.64 0.83
13 5.73 5.66 5.72 0.81 1.23 1.02
14 6.59 5.68 6.95 0.96 1.25 1.03
15 5.01 5.31 5.09 0.56 0.78 0.72
16 6.18 5.98 6.48 0.84 0.81 0.82
17 4.93 4.49 6.73 0.57 0.63 0.53
18 5.99 8.61 7.52 1.55 0.43 0.79
19 5.77 5.20 7.03 0.86 0.60 0.76
20 6.41 5.12 8.00 0.81 1.08 0.90
21 5.30 4.43 5.91 1.23 1.29 1.20
22 5.32 5.3 4.99 0.60 0.93 0.82
23 7.60 7.45 8.35 1.00 0.95 0.98
24 5.66 4.55 6.77 0.88 0.78 0.80
25 4.80 4.50 5.88 0.51 0.64 0.58
26 6.94 7.44 7.05 0.81 1.10 0.97
27 6.89 9.00 6.77 0.58 1.20 0.96
28 6.19 7.00 6.13 0.76 0.81 0.82
29 5.57 7.11 5.57 0.53 0.78 0.64
30 8.11 8.63 8.33 1.06 1.04 0.93
31 5.68 4.28 6.16 0.55 0.89 0.75
32 5.70 5.11 6.99 0.60 0.86 0.69
33 6.34 5.99 7.22 1.09 0.92 0.97
34 6.39 6.38 7.36 0.96 1.36 1.24
35 6.13 6.6 5.87 0.83 0.89 0.78
36 6.81 7.82 7.45 0.67 1.02 0.94
37 5.55 2.89 3.79 0.92 0.86 1.02
38 7.18 7.38 7.94 0.55 0.63 0.61
39 6.35 6.01 7.55 1.16 1.32 1.13
40 7.03 6.14 6.43 0.99 0.78 0.90
41 7.20 7.10 8.05 1.15 1.36 1.13
42 7.34 6.71 7.79 0.66 1.11 0.80
43 6.60 7.42 6.70 0.82 0.66 0.74
44 8.21 7.46 7.59 0.87 1.42 0.93
45 7.80 12.40 8.40 0.68 0.91 0.83
46 5.83 5.48 6.71 0.72 0.53 0.67
47 7.39 6.55 6.66 1.00 1.10 1.03
48 7.04 6.77 7.20 0.89 0.73 0.82
49 6.37 8.94 5.95 0.73 1.31 1.11
50 6.64 6.20 8.39 0.83 0.63 0.73
51 6.21 8.74 4.46 1.90 1.16 1.56
52 6.08 8.80 6.73 0.82 0.77 0.82
53 5.90 6.38 6.65 0.79 1.00 0.93
54 8.22 7.92 8.73 0.86 1.42 1.04
55 8.94 6.65 8.94 1.38 1.01 1.10
56 7.04 7.95 6.49 0.79 0.87 0.86
57 6.67 8.84 6.86 0.62 0.94 0.88
58 6.10 5.44 6.52 0.73 0.84 0.79
59 7.04 8.60 8.06 0.77 0.96 0.86
60 5.79 4.58 5.50 0.24 0.90 0.84
61 5.39 4.31 6.01 1.07 1.77 1.42
Mean  SD 6.25  0.98 6.22  1.34 6.70  1.17 0.86  0.26 0.98  0.28‡ 0.91  0.19
‡p  0.023 vs. MBF (ml/min/g) in infarct-related territory.
Beta-AR  beta-adrenoceptor; MBF  myocardial blood flow; ROI  region of interest.
Significance of myocardial beta-AR downregulation in
the nonfailing heart. A particular characteristic of the
present study was that, on average, our patients had well
preserved LV systolic function (mean ejection fraction
47%). Unlike patients with CHF (7), no significant increase
in circulating catecholamines was found in our patients
despite the demonstration of myocardial beta-AR down-
regulation. We have previously studied another condition,
HCM, in which myocardial beta-AR downregulation oc-
curs despite normal LV systolic function (13). Furthermore,
we demonstrated that in patients with HCM, the degree of
myocardial beta-AR downregulation was predictive of CHF
development at follow-up (9).
In a more recent PET study in patients with HCM (14),
we combined the measurement of postsynaptic myocardial
beta-AR density with that of presynaptic noradrenaline
reuptake-1 using the catecholamine analogue [11C]-
hydroxyephedrine. The data showed that beta-AR down-
regulation was associated with a reduced reuptake of [11C]-
hydroxyephedrine by neural terminals in the myocardium.
This reduced reuptake-1 leads to a less efficient disposal of
cathecolamines from the synaptic cleft, and we believe that
Figure 1. Regression line (n  61) through individual patients’ end-systolic volume change (ESV) (values at six months divided by those at one week),
plotted against the respective beta-adrenoceptor density as measured by positron emission tomography, one month post-acute myocardial infarction.
Figure 2. Regression line (n  61) through individual patients’ end-diastolic volume change (EDV) (values at six months divided by those at one week),
plotted against the respective beta-adrenoceptor density as measured by positron emission tomography, one month post-acute myocardial infarction.
1221JACC Vol. 40, No. 7, 2002 Spyrou et al.
October 2, 2002:1216–24 Myocardial Beta-AR After Acute Infarction
this contributes to myocardial beta-AR downregulation in
HCM. This supports the pathophysiologic model of Bris-
tow et al. (18), suggesting that increases in local neurotrans-
mitter concentrations rather than elevated circulating cat-
echolamines are probably responsible for myocardial
beta-AR downregulation (indeed, we found in the present
study that patients had lower circulating noradrenaline than
controls, whereas the adrenaline level was not different).
Although the data from the present study do not extend that
far, we hypothesize that a similar abnormality of regional
(i.e., confined to the heart) catecholamine turnover is
responsible for the downregulation observed in our post-
AMI patients.
Relation between beta-AR downregulation and LV re-
modeling. The way in which SNS activation affects LV
remodeling in the subacute phase after AMI, prior to the
development of heart failure, is not fully understood. Data
from studies of heart rate variability and baroreflex sensitiv-
ity (19,20) would suggest that neural drive to the heart
within the first four weeks after AMI is altered in the
direction of sympathetic predominance, and these indices
have prognostic significance. The data from the present
study are consistent with this and show that beta-AR
downregulation is diffuse, involving both infarcted and
remote myocardium and is predictive of LV dilation at
follow-up. In addition, other factors, such as the speed and
success of recanalization of the infarct-related artery (i.e.,
TIMI flow value), play an important role in determining the
degree of LV remodeling, as does infarct size (21).
The short-term benefits of this regional SNS activation
after infarction are apparent (e.g., in the maintenance of
cardiac output). It can be appreciated, however, that the
preservation of cardiac output may become dependent upon
greater degrees of sympathetic drive, and this sustained and
excessive activation may be maladaptive, as demonstrated in
both animal (22,23) and human studies (4,24–28).
Clinical implications. Treatment with angiotensin-
converting enzyme inhibitors has been shown to modify the
relationship among infarct size, CHF, and mortality after
AMI (5,25). It was suggested by the SAVE investigators (5)
that the mechanism of this might be a blunting of neuro-
humoral activation (29). With the recognition of the ben-
efits for mortality of beta-blockade treatment after AMI and
for established CHF (such as in the CIBIS, MOCHA,
MERIT-HF, COPERNICUS, and CAPRICORN studies
[30–33]), our data provide a further pathophysiological
basis for the efficacy of this class of drugs.
Methodologic considerations. Positron emission tomog-
raphy is a well-established method for the quantitative,
noninvasive measurement of regional myocardial radionu-
clide distribution in vivo (34). This technique has been used
for the quantification of regional MBF (12,17,35,37), me-
tabolism (38,39), and autonomic function (34). The hydro-
philic beta-AR antagonist S-CGP 12177 labeled with 11C
(S-[11C]CGP 12177) is an ideal ligand for the measure-
ment of total beta-AR density as it has a high affinity, is
nonselective and hydrophilic, does not cross the cell mem-
brane, and therefore binds only to the functionally active
cell-surface receptors (8,13). Previously, Merlet et al. (8)
reported a significant correlation between LV beta-AR
density measured by PET with [11C]CGP 12177 and
beta-AR density measured using in vitro binding of
[3H]CGP 12177 in LV endomyocardial biopsy specimens
taken from patients with idiopathic dilated cardiomyopathy
(r  0.79, p  0.019). In a previous study from our group,
myocardial beta-AR was measured twice in the same
patients using PET with [11C]CGP 12177, and the repro-
ducibility of the technique was 80% (13).
Finally, it is possible that the beta-AR density on the
myocytes is normal, but that the proportion of cardiac
myocytes relative to the other tissue components (e.g.,
fibrous tissue) is reduced in infarcted myocardium. To
minimize the effect of thinning and fibrosis in the infarcted
areas, all beta-AR values were corrected for partial volume
using the perfusible tissue index (15). This index is derived
from the H2
15O scan and provides an estimate of the
fraction of viable tissue within the volume of interest
capable of exchanging rapidly the freely diffusible tracer
H2
15O (15). Furthermore, beta-AR downregulation was
also demonstrated in remote, noninfarcted myocardium.
Thus, we consider that “dilution” of cardiac myocytes by
nonmyocyte tissue could only account at most for a small
Figure 3. Black bars those patients (n 41) whose left ventricular (LV)
volumes were found to be decreased six months after infarction; White
bars  those patients (n  20) whose LV volumes were found to be
increased six months after infarction. Beta-AR  myocardial beta-
adrenoceptor density.
Table 3. Relationship Between TIMI Flows and Left
Ventricular Volumes (Improved vs. Dilated) at Six Months
TIMI Flow Improved Dilated Totals
TIMI 1 1 1 2
TIMI 2 2 6 8
TIMI 3 38 13 51
Totals 41 20 61
A higher Thrombolysis In Myocardial Infarction (TIMI) score predicted an improved
left ventricular volume at six months (p  0.002).
1222 Spyrou et al. JACC Vol. 40, No. 7, 2002
Myocardial Beta-AR After Acute Infarction October 2, 2002:1216–24
part of the observed difference between infarcted and
noninfarcted regions.
Study limitations. The study was based on a single mea-
surement of beta-AR soon after AMI, as obviously the
occurrence of the infarct could not be predicted. However,
although a baseline beta-AR scan was not obtained before
AMI, by excluding patients with other potential causes of
SNS activation and LV remodeling, we should have mini-
mized the likelihood of a preexisting beta-AR downregula-
tion.
Finally, it is increasingly clear that genetic variability
(e.g., polymorphism of beta-AR, which was not assessed in
the present study) accounts for clinical variability in re-
sponse to a myocardial insult and adversely affects the
outcome of CHF (40).
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